Mpox vaccine, drug developers rally as virus spreads outside Africa, ET HealthWorld

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

Mpox vaccine, ***** developers rally as virus spreads outside *******, ET HealthWorld

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

By Lucy Raitano and Alun John

London: Shares in companies making and developing products against mpox surged on Friday as the ********* Union’s public health body raised its alert level for the virus spreading in ******* and beyond.

A new variant has spread rapidly in *******, prompting the World Health Organization to declare mpox a global public health emergency on Wednesday.

Europe’s ******** prevention agency said on Friday more imported cases will appear in the region, a day after Sweden reported its first case of mpox linked to the new strain.

Shares of Danish biotech firm Bavarian Nordic, which makes an mpox vaccine, jumped 20 per cent on Friday. They have climbed 50 per cent this week as concerns over the virus rise.

Shares in Emergent BioSolutions gained 15 per cent in U.S. trading. Its vaccine, approved for smallpox, has also been used as an mpox shot, but the U.S. Food and ***** Administration is yet to approve its application for use against the virus.

Jefferies analysts said in a note on Thursday they expect significant orders for Bavarian Nordic’s mpox vaccine due to the outbreak.

Up to roughly 3 million doses of the vaccine could potentially be made available in 2024 and 10 million in 2025, the Jefferies analysts said. Winning approval for administering to adolescents and children would be key, they said.

Shares in other companies involved in the mpox response have also swung wildly this week.

SIGA Technologies jumped 7 per cent on Friday, after falling nearly 20 per cent a day earlier after its mpox ***** ******* to meet the main goal in a study.

U.S.-listed Geovax Labs,, which had a market capitalization of less than $20 million as of Thursday, surged 60 per cent to $5.35 in early trading. The company is developing a vaccine against mpox and smallpox.

Bavarian Nordic’s shares closed up 17.8 per cent at 282.5 Danish crowns.

(Reporting by Lucy Raitano and Alun John in London, Manas Mishra and Puyaan Singh in Bengaluru, additional reporting by Samuel Indyk in London, editing by Susan Fenton and Sriraj Kalluvila)

• Published On Aug 17, 2024 at 06:41 AM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Download ETHealthworld App

• Get Realtime updates
• Save your favourite articles

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Scan to download App
data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

This is the hidden content, please

• Sign In
• or
• Sign Up

#Mpox #vaccine #***** #developers #rally #virus #spreads #******* #HealthWorld

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up